| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0022-1759(95)00038-C |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:002217599500038C?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:002217599500038C?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 7602128 |
| P50 | author | Deborah L. Birx | Q24239052 |
| P2093 | author name string | V. Kalyanaraman | |
| T. C. VanCott | |||
| S. C. Veit | |||
| P. Earl | |||
| P2860 | cites work | Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network | Q67685093 |
| Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors | Q67711120 | ||
| Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1 | Q68060547 | ||
| Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen | Q68833722 | ||
| Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine | Q72224793 | ||
| Jitters jeopardize AIDS vaccine trials | Q72593257 | ||
| Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1 | Q28246579 | ||
| Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules | Q30416805 | ||
| Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides | Q33560772 | ||
| Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein | Q34097650 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies | Q35930918 | ||
| Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies | Q36620408 | ||
| A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon | Q36629118 | ||
| Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate | Q36629169 | ||
| Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein | Q37675018 | ||
| Genetic comparison of HIV-1 isolates from Africa, Europe, and North America | Q39190767 | ||
| Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies. | Q40180278 | ||
| Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype | Q41048122 | ||
| Biological, serological, and genetic characterization of HIV-1 subtype E isolates from northern Thailand | Q41484751 | ||
| Broadly Neutralizing Monoclonal Antibodies to the V3 Region of HIV-1 Can Be Elicited by Peptide Immunization | Q43552446 | ||
| Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals | Q43691530 | ||
| A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity | Q43746833 | ||
| Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. | Q44021595 | ||
| Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients | Q44255828 | ||
| Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein | Q44509170 | ||
| Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. | Q44809362 | ||
| Neutralizing monoclonal antibodies to the AIDS virus | Q44940572 | ||
| Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing | Q45252128 | ||
| Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype | Q45779746 | ||
| A unique human immunodeficiency virus culture secreting soluble gp160. | Q45832856 | ||
| Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients | Q45838802 | ||
| HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope | Q45848174 | ||
| A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research | Q45860645 | ||
| Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction | Q45872593 | ||
| HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients | Q46794671 | ||
| Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. | Q51133592 | ||
| Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. | Q55241600 | ||
| HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide | Q55241966 | ||
| Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. | Q55242478 | ||
| Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis | Q58547252 | ||
| Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system | Q58547271 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biosensor | Q669391 |
| P304 | page(s) | 103-117 | |
| P577 | publication date | 1995-06-01 | |
| 1995-06-14 | |||
| P1433 | published in | Journal of Immunological Methods | Q15755939 |
| P1476 | title | Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen | |
| P478 | volume | 183 |
| Q33603494 | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates |
| Q37102810 | A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide |
| Q45746959 | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies |
| Q35886254 | Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. |
| Q35580892 | Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate |
| Q24561905 | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies |
| Q77798261 | Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development |
| Q33835295 | Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. |
| Q39550518 | Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV |
| Q35874414 | In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope |
| Q39549352 | Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus |
| Q37633417 | Native-like Env trimers as a platform for HIV-1 vaccine design |
| Q30431941 | Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 |
| Q35894716 | Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. |
| Q30894431 | Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate |
| Q34678977 | Reduction of animal use in human vaccine quality control: opportunities and problems |
| Q35089512 | Spying on HIV with SPR. |
| Q48622673 | The ferritin-like protein Frm is a target for the humoral immune response to Listeria monocytogenes and is required for efficient bacterial survival |
Search more.